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Traumatic brain injuryTraumatic brain injury (TBI) is followed by a state ofmetabolic dysfunction, affecting the ability of neurons to use
energy and support brain plasticity; there is no effective therapy to counteract the TBI pathology. Brain-derived
neurotrophic factor (BDNF) has an exceptional capacity to support metabolism and plasticity, which
highly contrasts with its poor pharmacological proﬁle. We evaluated the action of a ﬂavonoid derivative
7,8-dihydroxyﬂavone (7,8-DHF), a BDNF receptor (TrkB) agonist with the pharmacological proﬁle
congruent for potential human therapies. Treatment with 7,8-DHF (5 mg/kg, ip, daily for 7 days) was
effective to ameliorate the effects of TBI on plasticity markers (CREB phosphorylation, GAP-43 and
syntaxin-3 levels) andmemory function in Barnes maze test. Treatment with 7,8-DHF restored the decrease
in protein and phenotypic expression of TrkB phosphorylation after TBI. In turn, intrahippocampal
injections of K252a, a TrkB antagonist, counteracted the 7,8-DHF induced TrkB signaling activation and
memory improvement in TBI, suggesting the pivotal role of TrkB signaling in cognitive performance after
brain injury. A potential action of 7,8-DHF on cell energy homeostasis was corroborated by the normaliza-
tion in levels of PGC-1α, TFAM, COII, AMPK and SIRT1 in animals subjected to TBI. Results suggest a potential
mechanism by which 7,8-DHF counteracts TBI pathology via activation of the TrkB receptor and engaging
the interplay between cell energy management and synaptic plasticity. Since metabolic dysfunction is an
important risk factor for the development of neurological and psychiatric disorders, these results set a
precedent for the therapeutic use of 7,8-DHF in a larger context.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Traumatic brain injury (TBI) is associated with lowered capacity of
the brain for plasticity and with long-term disturbances in cognitive
function [1]. Most of the attempts to develop pharmaceutical
approaches to reduce the sequel of TBI have yielded unsuccessful results
[2] mostly based on the multifactorial character of the TBI pathology.
Therefore, approaches empowered with the capacity to normalize
several weaknesses affected by the TBI pathology likely have advan-
tages over conﬁned approaches. The therapeutic potential of brain-
derived neurotrophic factor (BDNF) is strong based on its pleiotropic
capacity [3]; however, limitations associated with the delivery of
BDNF into the brain, its poor pharmacokinetic proﬁle and short half
life [4] have rendered therapeutic intentions impractical.
The extraordinary capacity of BDNF to support several aspects of
brain plasticity and function, suggests that agents that stimulate the
TrkB receptor, without the poor pharmacokinetics of BDNF, can betive Biology and Physiology,
les E. Young Drive South, Los
.ideal therapeutic agent to combat the TBI pathology. BDNF and TrkB
signaling are reduced in the TBI pathology [5], thereby reducing
neuronal function and making neurons more vulnerable to secondary
challenges. 7,8-dihydroxyﬂavone (7,8-DHF) is a member of the
ﬂavonoid family of compounds present in fruits and vegetables, which
acts as a small molecule TrkB agonist [4]. The binding of 7,8-DHF to
the cysteine cluster 2 and leucine-rich region in the extracellular
domain of the TrkB receptor provokes TrkB receptor dimerization and
autophosphorylation, which leads to activation of downstream
signaling cascades similar to BDNF. In particular, 7,8-DHF has demon-
strated neuroprotective effects against oxidative stress incurred from
glutamate toxicity [6], decreases infarct volumes in stroke, and reduces
toxicity in an animal model of Parkinson's disease [4]. These features
portray 7,8-DHF as an ideal candidate to be used therapeutically to
counteract the effects of the TBI pathology.
Patients suffering from mild or moderate concussive injury
experience abnormalities in the control of brain metabolism [7,8]
and increased risk for secondary brain injury [9,10]. A growing line of
research indicates that approaches leading to promote energy
homeostasis are a productive strategy to support brain function [11],
and to counteract the pathogenesis of TBI [12]. The peroxisome
proliferator-activated receptor gamma coactivator-1alpha (PGC-1α) is
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maintain mitochondrial homeostasis [13], including nuclear respiratory
factors (NRFs). The NRFs activate themitochondrial transcription factor
A (TFAM) that regulatesmitochondrial DNA (mtDNA) transcription and
replication [14,15]. The adenosine monophosphate-activated protein
kinase (AMPK) acts as an energy sensor in the cell and regulates
PGC-1α [16]. In turn, PGC-1α can also inﬂuence neuronal plasticity by
acting on BDNF [17]. BDNF supports a range of metabolic events,
which are crucial for neuronal function [18,19], and they are compro-
mised in the TBI pathology. Therefore, we sought to activate the TrkB
receptor using the safety proﬁle of 7,8-DHF to counteract energy
dysfunction, enhance plasticity, and improve behavioral performance
after TBI.
2. Materials and methods
2.1. Animals and experimental design
Male Sprague–Dawley rats (Charles River Laboratories, Inc.,
Wilmington, MA) approximately 2 months old were housed in
polyacrylic cages and maintained under standard housing conditions
(room temperature 22–24 °C) with 12 h light/dark cycle. All animals
had free access to food and drinking water. After acclimatization for
1 week on standard rat chow, the rats were trained on the Barnes
maze test for 5 days to learn the task, and then subjected to the
either sham or ﬂuid percussion injury (FPI). All animals received
intraperitoneal injections (1 ml/kg) of either 7,8-dihydroxyﬂavone
(7,8-DHF; 5 mg/kg, ip) or vehicle (VEH; 30% DMSO in PBS) once daily
for 7 consecutive days, starting from the day of injury till 2 h prior to
the memory retention behavior. 7,8-DHF (TCI America, OR, USA)
was dissolved in phosphate-buffered saline (PBS) containing 30%
dimethylsulfoxide (DMSO) and prepared fresh daily. The dose of
7,8-DHF was chosen on the basis of previous in vivo studies [4,20,21],
which demonstrated that systemic administration of 7,8-DHF leads
to central TrkB activation, and related behavioral changes. Memory
retention was tested by Barnes maze after 1 week of injury and
the animals were sacriﬁced immediately by decapitation for tissue
collection (Fig. 1). Based on the injury (sham vs. FPI) and treatment
(VEH vs. 7,8-DHF), there were four experimental groups (n = 7 per
group): (I) sham plus vehicle (sham/VEH); (II) sham plus 7,8-
dihydroxyﬂavone (sham/7,8-DHF); (III) ﬂuid percussion injury
plus vehicle (FPI/VEH); and (IV) ﬂuid percussion injury plus 7,8-
dihydroxyﬂavone (FPI/7,8-DHF).
In order to validate that the effects of 7,8 DHF occurred via the trkB
receptor, a separate set of animals was given a single unilateral
intrahippocampal injection of K252a (a TrkB antagonist) bound to
ﬂuorescence latex microspheres (Lumaﬂour Corp., FL, USA), or micro-
sphere vehicle as a control (n = 7 per group). The treatments were asBarnes Maze 
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Fig. 1. Schematic timeline representing experimental design: Rats were subjected to 5 days tra
animals received intraperitoneal injection (1 ml/kg) of either vehicle (VEH; 30% DMSO in PBS)
from the day of injury till 2 h prior to thememory retention test. Memory retention was tested
collection.follows: microspheres vehicle injected group followed by FPI and
7,8-DHF (VEH/FPI/7,8-DHF) and K252a injected group followed by FPI
and 7,8-DHF (K252a/FPI/7,8-DHF). FPI and 7,8-DHF (5 mg/kg, ip)
treatments were given beginning on the third day following the
intrahippocampal injection. Memory retention was tested by Barnes
maze 1 week post FPI, and animals were sacriﬁced immediately
following the test via decapitation.
All experiments were performed in accordance with the United
States National Institutes of Health Guide for the Care and Use of Labo-
ratory Animals and were approved by the University of California at Los
Angeles (UCLA) Chancellor's Animal Research Committee (ARC). The
suffering and number of animals used were minimized.
2.2. Administration of K252a into the hippocampus
Themicrosphereswere coatedwith K252a (46.8 ng/μl sterile water)
by passive absorption, according to previously described methods
[22,23]. The concentration of K252awas chosen based on its effective
blockade for BDNF receptor TrkB [23,24]. Prior to injection, 2–5%
isoﬂurane anesthesia was administered to the rats using a Mobile
Laboratory Animal Anesthesia System (VetEquip Inc., CA, USA). The
rats were positioned in a stereotaxic apparatus to secure the sight
for the injection. Vehicle or K252a imbedded in microspheres was
injected directly into the left hippocampus (3.8 mm posterior to
bregma, 2.6 mm lateral to midline and 3.7 mm vertical from skull)
using a Hamilton syringe in a volume of 2 μl over 15 min. After the
injection, the skull was sutured and the rats were placed in a heated
recovery chamber before being returned to their home cages.
2.3. Fluid percussion injury
The injury was performed as previously described [25]. In brief, the
animals were anesthetized by 2–5% isoﬂurane mixed with 100% O2
using a Mobile Laboratory Animal Anesthesia System (VetEquip Inc.,
CA, USA). A 3.0-mm-diameter craniotomy was made over the left
parietal cortex, 3.0 mm posterior to bregma and 6.0 mm lateral (left)
to themidlinewith a high-speeddrill (Dremel,WI, USA). A plastic injury
cap was placed over the craniotomy with silicone adhesive and dental
cement. When the dental cement hardened, the cap was ﬁlled with
0.9% saline solution. Anesthesia was discontinued and the injury cap
was attached to the ﬂuid percussion device. At the ﬁrst sign of hind-
limb withdrawal to a paw pinch, a moderate ﬂuid percussion pulse
(2.7 atm) was administered to the epidural space. Immediately upon
responding to a paw pinch, anesthesia was restored and the skull was
sutured. Neomycin was applied on the suture and the rats were placed
in a heated recovery chamber before being returned to their cages.
Sham animals underwent an identical preparation with the exception
of the lesion.9 12
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or 7,8-dihydroxyﬂavone (7,8-DHF; 5 mg/kg, ip) once daily for 7 consecutive days, starting
by Barnes maze at 7 days of injury and the animals were sacriﬁced immediately for tissue
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All rats were tested on the Barnes maze before and after experimen-
tal exposure to assess the cognitive functions [26]. In brief, our maze
was manufactured from acrylic plastic to form a disk 1.5 cm thick and
115 cm in diameter, with 18 evenly spaced 7 cm holes at its edges.
The disk was brightly illuminated by four overhead halogen lamps to
provide an aversive stimulus. The animals were trained to locate a
dark escape chamber hidden underneath a hole positioned around the
perimeter of a disk. All trials were recorded simultaneously by a video
camera installed directly overhead at the center of the maze. The
animals were trained with two trials per day for ﬁve consecutive days
before being subjected to the experimental conditions. A trial was
started by placing the animal in the center of the maze covered under
a cylindrical start chamber; after a 10 s delay, the start chamber was
raised. A training session ended after the animal had entered the
escape chamber or when a pre-determined time (5 min) had elapsed,
whichever came ﬁrst. Memory retention was tested during Barnes
maze trials performed oneweek after injury. All surfaceswere routinely
cleaned before and after each trial to eliminate possible olfactory cues
from preceding animals.
2.5. Tissue collection
After the memory test the animals were killed immediately by
decapitation and the fresh brains were dissected out, frozen in dry ice
and stored at−70 °C until use.
2.6. Immunobloting
The hippocampal tissues from the left hemisphere were homoge-
nized in a lysis buffer containing 137 mM NaCl, 20 mM Tris–HCl
pH 8.0, 1% NP40, 10% glycerol, 1 mM phenylmethylsulfonylﬂuoride
(PMSF), 10 μg/ml aprotinin, 0.1 mM benzethonium chloride, 0.5 mM
sodium vanadate. The homogenates were then centrifuged, the super-
natants were collected and total protein concentration was determined
according to MicroBCA procedure (Pierce, IL, USA), using bovine serum
albumin (BSA) as standard.
Brieﬂy, protein samples were separated by electrophoresis on a
10% polyacrylamide gel and electrotransferred to a PVDF membrane
(Millipore, MA, USA). Non-speciﬁc binding sites were blocked in
Tris-buffered saline (TBS), pH 7.6, containing 5% non-fat dry milk.
Membranes were rinsed in buffer (0.05% Tween-20 in TBS) and
then incubated with anti-actin or anti-BDNF, anti-pTrkB, anti-TrkB,
anti-AMPK, anti-cytochrome c oxidase II (COII), anti-mtTFA
(TFAM), anti-GAP-43, anti-syntaxin-3 (1:500; Santa Cruz Biotech-
nology, CA, USA), anti-PGC-1α, anti-SIRT1, anti-pCREB, anti-CREB
(1:1000, Millipore, MA, USA), anti-pAMPK (1:1000; Cell signaling
technology, MA, USA) followed by anti-rabbit or anti-goat or anti-
mouse IgG horseradish peroxidase-conjugate (1:10,000; Santa
Cruz Biotechnology, CA, USA). After rinsing with buffer, the
immunocomplexes were visualized by chemiluminescence using
the ECL kit (Amersham Pharmacia Biotech Inc., NJ, USA) according
to the manufacturer's instructions. The ﬁlm signals were digitally
scanned and then quantiﬁed using ImageJ software. Actin was
used as an internal control for western blot such that data were
standardized according to actin values.
2.7. Immunohistochemistry
Additional rats (n = 4) from each group were anesthetized with
isoﬂurane, then intracardially perfused with PBS (pH 7.4) followed by
4% paraformaldehyde in phosphate buffer (pH 7.4) and 30% sucrose in
paraformaldehyde. Tissues were ﬂash frozen on dry ice and stored
at −80 °C. For immunoﬂuorescence staining, serial coronal brain
sections (30 μm) were cut on a cryostat and collected into 0.01 Mphosphate buffered saline (PBS). After washing, free-ﬂoating sections
were heated to 80 °C for 30 min in 10 mM sodium citrate buffer
(pH 8.5) to promote antigen binding and allowed to return to room
temperature. Non-speciﬁc binding was blocked by incubating the
sections with 0.01 M PBS solution containing 0.5% BSA and 0.5% Triton
X-100 for 2 h at room temperature. Sections were then incubated
with rabbit polyclonal anti-pTrkB receptor (Y816) primary antibody at
a dilution of 0.3 μg/ml (a kind gift from Dr. Moses Chao) or mouse
monoclonal anti-GAP-43 primary antibody (1:250; Santa Cruz Biotech-
nology, CA, USA), in 0.01 M PBS solution containing 0.2% BSA and 0.6%
Triton X-100 at 4 °C overnight. After thorough washing with 0.01 M
PBS, the sections were incubated with rabbit or mouse secondary
antibody (Cy3; 1:250; FITC; 1:250, Jackson Immunoresearch; West
Grove, PA, USA) for 1.5 h at room temperature. The sections were
mounted using Prolong Gold antifade reagent (Life technologies, New
York, NY, USA). The staining was visualized under Zeiss microscope
(Zeiss Imager.Z1; Gottingen, DE) using the Axiovision software
(Carl Zeiss Vision, version 4.6).
For brightﬁeld staining, serial coronal brain sections (30 μm)
were cut on a cryostat, collected free-ﬂoating in 0.01 M PBS. Tissue
sections were processed for localization of syntaxin-3 according to
immunohistochemical procedures described previously [27]. After
washing in 0.01 M PBS, the sections were incubated with goat poly-
clonal anti-syntaxin-3 (1:250; Santa Cruz Biotechnology, CA, USA)
antibody overnight at 4 °C. Following incubation, the sections were
washed with 0.01 M PBS and incubated for 1.5 h in biotinylated
secondary antibody at room temperature. Antibody binding was
visualized using the avidin–biotin–horseradish peroxidase complex
(Vectastain ABC Kit, Vector Laboratories, CA, USA) and subsequently
enhanced by DAB-nickel (DAB Peroxidase Substrate kit Vector
Laboratories, CA, USA) incubation. The rinsed sections were then
mounted on gelatin-coated glass slides, dehydrated, cleared, and
coverslipped. The staining was visualized under Zeiss microscope
(Zeiss Imager.Z1; Gottingen, DE) using the Axiovision software
(Carl Zeiss Vision, version 4.6).
2.8. Statistical analysis
The results are represented as mean ± standard error of the mean
(SEM). Protein results are expressed as percentage of sham/VEH
group and statistical analysis was performed by two-way ANOVA
[(injury: sham vs. FPI) and (treatment: VEH vs. 7,8-DHF)]. Post-hoc
analyses were conducted using Bonferroni's multiple comparison tests
to determine the signiﬁcance of difference among various groups. The
results of K252a experiments were analyzed by one-way ANOVA
followed by Bonferroni's multiple comparison tests. A level of 5%
probability was considered as statistically signiﬁcant. Pearson correla-
tion analysis was performed on individual samples to evaluate the
association between variables.
3. Results
3.1. 7,8-DHF reduces cognitive dysfunction after TBI
All animals were tested for spatial learning in the Barnes maze for
5 days before being subjected to the experimental conditions. All groups
showed a decrease in latency time to ﬁnd the escape hole from ﬁrst to
last day of training, and showed similar latency time on last day
(day 5), suggesting the rats were in the same cognitive condition before
starting the experiments (data not shown).
Oneweek after injury, a Barnesmaze test was performed for 1 day to
evaluate memory retention in vehicle and 7,8-DHF treated animals.
Two-way ANOVA analysis showed a signiﬁcant effect of injury
(F1,24 = 12.71, p b 0.01) and treatment (F1,24 = 6.79, p b 0.05), and an
interaction between injury vs. treatment (F1,24 = 4.51, p b 0.05) for
the latency time in Barnes maze. The post-hoc analysis showed a
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Fig. 2. Comparison of latency times in Barnes maze test in vehicle (VEH) and 7,8-
dihydroxyﬂavone (7,8-DHF; 5 mg/kg, ip) treated rats, subjected to either sham or ﬂuid
percussion injury (FPI). Values are expressed as mean ± SEM. ##p b 0.01 vs. sham/VEH;
∗p b 0.05 vs. FPI/VEH; ANOVA (two-way) with Bonferroni's comparisons post-hoc test.
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which is indicative of memory impairment (FPI/VEH vs. sham/VEH,
p b 0.01). In turn, the treatment with 7,8-DHF in TBI animals resulted
in a signiﬁcant reduction in latency time (FPI/7,8-DHF vs. FPI/VEH,
p b 0.05), whereas 7,8-DHF per se did not affect the cognitive state of
animals (sham/7,8-DHF vs. sham/VEH, p N 0.05). These results indicate
that 7,8-DHF confers protection against TBI induced memory deﬁcits
(Fig. 2). The vehicle used for solubilizing 7,8 DHF was (30% DMSOA
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Fig. 3. (A) Levels of TrkB phosphorylation, (B) correlation analysis of TrkB phosphorylation
dihydroxyﬂavone (7,8-DHF; 5 mg/kg, ip) treated rats, subjected to either sham or ﬂuid pe
#p b 0.05, ##p b 0.01 vs. sham/VEH; ∗∗p b 0.01 vs. FPI/VEH; ANOVA (two-way) with Bonfer
hippocampal coronal sections from vehicle and 7,8-DHF (5 mg/kg, ip) treated groups, subjectein PBS), which may have some independent effect on memory,
however we observed no differences in behavioral outcomes between
(30% DMSO in PBS) and PBS injected animals (data not shown).3.2. 7,8-DHF treatment restores activation of TrkB signaling in TBI
We quantiﬁed the levels of BDNF and its receptor TrkB phosphoryla-
tion in animals treated with 7,8-DHF with or without TBI. The injury
(F1,24 = 14.28, p b 0.01) and treatment (F1,24 = 28.12, p b 0.01) had
signiﬁcant effects on the phosphorylation of TrkB, as observed by
ANOVA (two-way) analysis. Post-hoc analyses showed that treat-
ment with 7,8-DHF enhanced TrkB phosphorylation in sham animals
(sham/7,8-DHF vs. sham/VEH, p b 0.05). TBI reduced the phosphory-
lation of TrkB (FPI/VEH vs. sham/VEH, p b 0.05), which was amelio-
rated by the treatment with 7,8-DHF (FPI/7,8-DHF vs. FPI/VEH,
p b 0.01), arguing in favor of the therapeutic potential of 7,8-DHF
(Fig. 3A). TrkB phosphorylation changed in inverse proportion to
the latency time in Barnes maze (r =−0.539, p b 0.01), suggesting
an association between TrkB signaling and memory performance
(Fig. 3B). Additionally, we analyzed the effects of FPI and 7,8-DHF
on the phenotypic expression of hippocampal TrkB phosphorylation
using immunoﬂuorescence staining. FPI showed a qualitative
decrease in the labeling for phosphorylated TrkB receptor, particu-
larly in the CA3 subﬁeld. In turn, the treatment with 7,8-DHF showed
a qualitative increase in pTrkB expression in both sham and FPI
animals (Fig. 3C).0
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based on the capacity of 7,8-DHF to work as a BDNF analog on TrkB
receptor activation. Two-way ANOVA analysis showed a signiﬁcant
effect of injury (F1,24 = 34.17, p b 0.01) on BDNF levels. Post-hoc
test showed a signiﬁcant decrease in BDNF levels in animals subjected
to TBI (FPI/VEH vs. sham/VEH, p b 0.01). The treatment with 7,8-DHF
did not affect the levels of BDNF in sham (sham/7,8-DHF Vs sham/
VEH, p N 0.05) or in animals subjected to TBI (FPI/7,8-DHF Vs FPI/VEH,
p N 0.05; Fig. 3D).
3.3. Intrahippocampal K252a counteracts the beneﬁcial effect of 7,8-DHF
in TBI
Since 7,8-DHF is as selective TrkB agonist, therefore, we have studied
the effect of a TrkB antagonist, K252a on memory functions and TrkB
activation in 7,8-DHF treated TBI animals, to determine whether the
activation of TrkB signaling is the underlying basis for the regulation
of cognitive performance. Results showed that intrahippocampal injec-
tion of K252a counteracted thememory improving action of 7,8-DHF in
TBI as evidenced by an increased latency time on Barnesmaze in K252a-
pretreated TBI animals, subjected to the 7,8-DHF treatment (K252a/FPI/
7,8-DHF vs.VEH/FPI/7,8-DHF, p b 0.01; Fig. 4A). According to our results,
K252a also ameliorated the 7,8-DHF induced TrkB phosphorylation in
animals subjected to TBI (K252a/FPI/7,8-DHF vs. VEH/FPI/7,8-DHF,
p b 0.05; Fig. 4B). We assessed the effect of K252a on TrkB downstreamA
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Fig. 4. Effects of K252a (46.8 ng/μl), a TrkB antagonist, on 7,8-dihydroxyﬂavone (7,8-DHF; 5mg
in rats subjected to the ﬂuid percussion injury (FPI). K252a coated ﬂuorescence latex micro
ﬂuorescence latex microspheres were used as a vehicle. Data for TrkB phosphorylation are ex
7,8-DHF; ANOVA (one-way) with Bonferroni's comparisons post-hoc test.signaling molecules such as CREB and PGC-1α. The data show that
intrahippocampal injection of K252a counteracted the effects of
7,8-DHF on CREB phosphorylation and levels of PGC-1α in animals
subjected to TBI (K252a/FPI/7,8-DHF vs. VEH/FPI/7,8-DHF, p b 0.05;
Fig. 4C and D). These results provide evidence for a role of TrkB
signaling for the action of 7,8-DHF on CREB and PGC-1α, and a
possible role in rescuing a memory deﬁcit.
3.4. 7,8-DHF treatment counteracts the reduction of molecules associated
with brain plasticity in TBI
We assessed cAMP-response element binding (CREB) protein, a
family of transcription factors that play a major role in synaptic plastic-
ity and cognitive functions [28]. The phosphorylation of CREB changed
signiﬁcantly with injury (F1,24 = 21.79, p b 0.01) and treatment
(F1,24 = 27.30, p b 0.01) according to ANOVA (two-way) analysis.
Post-hoc analysis showed that the 7,8-DHF elevated the phosphoryla-
tion of CREB in sham animals (sham/7,8-DHF vs. sham/VEH, p b 0.01).
TBI reduced the levels of CREB phosphorylation (FPI/VEH vs. sham/
VEH, p b 0.05), whereas the treatment with 7,8-DHF restored the levels
of CREB phosphorylation in animals subjected to TBI (FPI/7,8-DHF vs.
FPI/VEH, p b 0.05) such that they were not different from sham/VEH
controls (Fig. 5A).
We assessed the levels of GAP-43, a growth associated protein,
which provides an index of growth or plasticity as it is expressed atB
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Fig. 5. (A) Levels of CREBPhosphorylation, (B) levels of GAP-43 and (D) syntaxin-3 in vehicle (VEH) and 7,8-dihydroxyﬂavone (7,8-DHF; 5mg/kg, ip) treated rats, subjected to either sham
orﬂuid percussion injury (FPI). Data are expressed as percentage of sham/VEH (mean± SEM). #p b 0.05, ##p b 0.01 vs. sham/VEH; ∗p b 0.05, ∗∗p b 0.01 vs. FPI/VEH; ANOVA (two-way)with
Bonferroni's comparisons post-hoc test. (C) Immunoﬂuorescence staining of GAP-43 (FITC) in hippocampal coronal sections from vehicle and 7,8-DHF (5 mg/kg, ip) treated groups,
subjected to either sham or FPI (scale bar: 20 μm). (E) Brightﬁeld staining of syntaxin-3 in hippocampal coronal sections from sham/VEH, FPI/VEH and FPI/7,8-DHF (5 mg/kg, ip) groups
(scale bars: 100 and 50 μm).
867R. Agrawal et al. / Biochimica et Biophysica Acta 1852 (2015) 862–872high levels during development and axonal regeneration [29]. Two-way
ANOVA revealed a signiﬁcant effect of injury (F1,24 = 12.33, p b 0.01)
and treatment (F1,24 = 24.15, p b 0.01) for the levels GAP-43. Thepost-hoc test showed that TBI reduced the levels of GAP-43 (FPI/VEH
vs. sham/VEH, p b 0.01), whereas the treatment with 7,8-DHF
counteracted the effect of TBI on GAP-43 (FPI/7,8-DHF vs. FPI/VEH,
868 R. Agrawal et al. / Biochimica et Biophysica Acta 1852 (2015) 862–872p b 0.01; Fig. 5B). There was a marked qualitative reduction in GAP-43
immunoreactivity within the pyramidal cells of CA3 subregion in TBI,
which was restored after the treatment with 7,8-DHF (Fig. 5C).
We have also assessed the levels of syntaxin-3, a protein responsible
for transporting vesicles, which participates in exocytosis and also plays
important role in the growth of neuritis [30]. The levels of syntaxin-3
changed signiﬁcantly with injury (F1,24 = 5.67, p b 0.05) and treatment
(F1,24 = 13.93, p b 0.01, two-way ANOVA). Post-hoc analyses showed a
signiﬁcant decrease in the levels of syntaxin-3 in animals subjected to
the TBI (FPI/VEH vs. sham/VEH, p b 0.05). The 7,8-DHF per se did not
affect the levels of syntaxin-3 (sham/7,8-DHF vs. sham/VEH, p N 0.05),
while the treatment with 7,8-DHF restored the levels of synatxin-3 in
TBI (FPI/7,8-DHF vs. FPI/VEH, p b 0.01; Fig. 5D). Further, we have
analyzed the effects of FPI and 7,8-DHF on the phenotypic expression
of syntaxin-3 using immunohistochemistry. Syntaxin-3 staining was
predominantly distributed in the apical and basal dendrites of CA1
pyramidal cells and in the granule cells of the dentate gyrus (DG) of
the hippocampal formation. FPI resulted in reduced syntaxin-3 staining
in CA1 and DG, which was counteracted by the treatment with 7,8-DHF
(Fig. 5E).
3.5. 7,8-DHF treatment normalizes alterations inmolecules associated with
mitochondrial biogenesis after TBI
We examined the levels of PGC-1α, which is amember of a family of
transcription co-activators that plays a central role in mitochondrial
biogenesis. Two-way ANOVA analysis revealed a signiﬁcant effect of
injury (F1,24 = 6.15, p b 0.05) and treatment (F1,24 = 14.74, p b 0.01),
as well as their interaction (F1,24 = 29.53, p b 0.01) on PGC-1α. The0
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Fig. 6. (A) Protein levels of PGC-1α, (B) correlation analysis of PGC-1αwith latency time in B
latency time in Barnes maze test in vehicle (VEH) and 7,8-dihydroxyﬂavone (7,8-DHF; 5 mg
expressed as percentage of sham/VEH (mean ± SEM). ##p b 0.01 vs. sham/VEH; ∗p b 0.05, ∗∗ppost-hoc analysis showed that TBI negatively inﬂuences the levels of
PGC-1α (FPI/VEH vs. sham/VEH, p b 0.01). The treatment with
7,8-DHF counteracted the effect of brain trauma on levels of PGC-1α
(FPI/7,8-DHF vs. FPI/VEH, p b 0.01; Fig. 6A). We also observed that the
levels of PGC-1αwere negatively correlatedwith latency time in Barnes
maze test (r =−0.527, p b 0.01) suggesting that an increased PGC-1α
may contribute to improvement in memory function (Fig. 6B).
To analyze the role of TrkB activation on the maintenance of
mitochondrial protein function after TBI, we quantiﬁed the mitochon-
drial transcription factor A (TFAM). A signiﬁcant interaction between
treatment vs. injury (F1,24= 22.64, p b 0.01) was observed for the levels
of TFAM using two-way ANOVA. The post-hoc test performed for
multiple comparisons showed that TBI resulted in a signiﬁcant reduc-
tion in the levels of TFAM (FPI/VEH vs. sham/VEH, p b 0.01). In turn,
the treatment with 7,8-DHF, signiﬁcantly ameliorated the impact of
TBI on TFAM protein levels (FPI/7,8-DHF vs. FPI/VEH, p b 0.01; Fig. 6C).
We assessed the levels of mitochondrial cytochrome oxidase II
(COII), which provides an index of mitochondrial function/mass and
plays an important role in mitochondrial oxidative phosphorylation. A
signiﬁcant effect of injury (F1,24 = 24.90, p b 0.01) and treatment
(F1,24 = 7.90, p b 0.05) as well as a signiﬁcant interaction between
injury vs. treatment (F1,24=4.59, p b 0.05)were observed on COII levels
using two-way ANOVA. The post-hoc analysis showed that COII levels
were reduced after brain injury (FPI/VEH vs. sham/VEH, p b 0.01),
while the treatment with 7,8-DHF maintained the levels of COII after
TBI (FPI/7,8-DHF vs. FPI/VEH, p b 0.05; Fig. 6D). The negative correlation
between latency time and level of COII (r =−0.663, p b 0.01) suggests
that memory function tested in the Barnes maze may rely on the levels
of mitochondrial proteins (Fig. 6E).C
120 150
m/VEH)
Sham/VEH
Sham/7,8-DHF
FPI/VEH
FPI/7,8-DHF
r = -0.527
P<0.01
0
20
40
60
80
100
120
Sham/VEH Sham/7,8-
DHF
FPI/VEH FPI/7,8-
DHF
T
F
A
M
/a
c
ti
n
 (
%
 o
f 
S
h
a
m
/V
E
H
)
##
**
0 30 60 90 120 150
COII/actin (% of Sham/VEH)
Sham/VEH
Sham/7,8-DHF
FPI/VEH
FPI/7,8-DHF
r = -0.663
P<0.01
E
arnes maze test, (C) TFAM levels, (D) COII levels and (E) correlation analysis of COII with
/kg, ip) treated rats, subjected to either sham or ﬂuid percussion injury (FPI). Data are
b 0.01 vs. FPI/VEH; ANOVA (two-way) with Bonferroni's comparisons post-hoc test.
869R. Agrawal et al. / Biochimica et Biophysica Acta 1852 (2015) 862–8723.6. 7,8-DHF counteracted alterations in markers of energy management
following TBI
We evaluated the effects of FPI and 7,8-DHF on AMP activated
protein kinase (AMPK), a protein that controls the balance and
transduction of cellular energy. A two-way ANOVA analysis (injury vs.
treatment) indicated a signiﬁcant effect of injury (F1,24 = 272.35,
p b 0.01) and treatment (F1,24 = 104.90, p b 0.01), and an interaction
between 7,8-DHF vs. injury (F1,24 = 53.81, p b 0.01) for AMPK
phosphorylation. The Bonferroni post-hoc test formultiple comparisons
showed that TBI reduced the levels of AMPK phosphorylation (FPI/VEH
vs. sham/VEH, p b 0.01), while the 7,8-DHF treatment appeared to
protect the brain against the effects of the injury as the levels of AMPK
phosphorylation was signiﬁcantly high in 7,8-DHF treated group
subjected to FPI (FPI/7,8-DHF vs. FPI/VEH, p b 0.05). The treatment
with 7,8-DHF also elevated levels of AMPK phosphorylation in sham
animals (sham/7,8-DHF vs. sham/VEH, p b 0.01; Fig. 7A).
Based on the demonstrated role of sirtuin 1 (SIRT1) in cell energy
metabolism, we have evaluated the effects of FPI and 7,8-DHF on
SIRT1. Two-way ANOVA analysis showed a signiﬁcant effect of injury
(F1,24 = 30.49, p b 0.01) and treatment (F1,24 = 11.64, p b 0.01), and
signiﬁcant interaction between injury vs. treatment (F1,24 = 8.21,
p b 0.01). Levels of SIRT1 were reduced after TBI in comparison to the
sham group (FPI/VEH vs. sham/VEH, p b 0.01). Treatment with
7,8-DHF ameliorated the effect of TBI on SIRT1 as evidenced by a
signiﬁcant increase in SIRT1 level in 7,8-DHF animals subjected to TBI
(FPI/7,8-DHF vs. FPI/VEH, p b 0.01; Fig. 7B).
4. Discussion
We assessed the capacity of the TrkB receptor agonist 7,8-DHF to
counteract the effects of TBI on cognitive function. According to our
results, systemic administration of 7,8-DHF signiﬁcantly attenuated
disrupted memory function by activating hippocampal TrkB receptor,
evidenced by the counteracting action of K252a, a TrkB antagonist, on
7,8-DHF induced memory improvement and TrkB activation in TBI. In
addition, the 7,8-DHF treatment was effective to ameliorate the effects
of TBI on CREB phosphorylation, GAP-43, and syntaxin-3 levels. These
effects engaged molecular systems related to energy homeostasis
(AMPK and SIRT1) and mitochondrial biogenesis (PGC-1α, TFAM and
COII), indicating that activation of cellular energy metabolism may be
an important step for the action of 7,8-DHF on plasticity. These ﬁndingsA
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Fig. 7. (A) Phosphorylation of AMPK and (B) levels of SIRT1 in vehicle (VEH) and 7,8-dihydrox
injury (FPI). Data are expressed as percentage of sham/VEH (mean ± SEM). ##p b 0.01 vs. sham
post-hoc test.emphasize the potential of 7,8-DHF as an efﬁcacious and non-invasive
therapeutic agent to downgrade the TBI pathology. Our results also
indicate that dysfunction in the BDNF system is a crucial step by
which TBI compromises the capacity of cell to metabolize energy
necessary for normal cognitive processing.
4.1. BDNF-TrkB signaling system and cognitive functions
BDNF-TrkB signaling is critically important for cell functioning
such that dysfunction of TrkB has been implicated in various neuro-
degenerative diseases and psychiatric disorders [31]. The capacity of
BDNF-TrkB signaling to engage metabolism and plasticity makes it a
suitable therapeutic target for counteracting the pathology associated
with TBI. 7,8-DHF is a member of the ﬂavonoid family, which, similar
to BDNF has a high binding afﬁnity for the TrkB receptor. Furthermore,
7,8-DHF crosses the blood brain barrier and has a safe pharmacokinetic
proﬁle, making it an excellent therapeutic agent [4,32]. According to our
results, TBI reduces the levels of molecular systems related to BDNF,
including phosphorylation of the TrkB receptor. In turn, the treatment
with 7,8-DHF was able to attenuate the effect of TBI on the activation
and phenotypic expression of TrkB without affecting endogenous
BDNF levels, which indicates that systemic administration of 7,8-DHF
directly activates TrkB. In addition, our ﬁndings show that 7,8-DHF
rescues hippocampal-dependent cognitive deﬁcit in TBI, which is
negatively correlated with TrkB phosphorylation. Together these data
provide an indication for the importance of TrkB activation in main-
taining cognitive functions during TBI, which is in agreement with
previous reports showing that systemic 7,8-DHF can ameliorate the
memory deﬁcit through restoring TrkB dysfunction in transgenic
mouse model of Alzheimer's disease [21]. Furthermore, our results
showing the obstructive ability of K252a against memory improve-
ments and TrkB signaling activation following 7,8-DHF treatment
corroborate the pivotal role of TrkB signaling on cognitive recovery
after TBI.
4.2. Mitochondrial biogenesis
TBI occurrence compromises molecular systems involved in mito-
chondrial biogenesis via inﬂuencing transcription factors that are im-
portant for maintaining neuronal plasticity. In particular, PGC-1α is a
co-transcriptional regulator that activates various transcription factors,
including nuclear respiratory factors (NRFs). In turn, the NRFs activateB
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870 R. Agrawal et al. / Biochimica et Biophysica Acta 1852 (2015) 862–872the mitochondrial transcription factor TFAM, which stimulates mtDNA
transcription. Our results show that treatment with 7,8-DHF restored
levels of PGC-1α and TFAM,whichwere reduced after TBI, emphasizing
the role of TrkB activation in maintaining a homeostatic balance during
energy crisis. Our ﬁndings showing that latency time in Barnes maze
was reduced in proportion to increased in PGC-1α, support the action
of PGC-1α on maintaining behavioral performance.
PGC-1α is a potent coactivator of a plethora of transcription factors
that inﬂuence cellular energy andmitochondrial functions by activating
the mitochondrial proteins such as cytochrome C oxidase II (COII). COII
is a protein subunit of the terminal and highly regulated enzyme
complex IV of the electron transport chain in mitochondria [27]. COII
plays a key role in controlling ATP production as it helps to establish a
transmembrane difference of proton electrochemical potential in the
electron transport chain of mitochondria. We observed a signiﬁcant
decline in COII levels after TBI reﬂecting the action of TBI on energy
depression. The fact that COII levelswere restored by7,8-DHF treatment
supports the concept that 7,8-DHF is beneﬁcial for the maintenance of
cellular energy. Similar to our results for PGC-1α, we observed that
latency time in the Barnes maze was inversely proportional to COII
levels, emphasizing the role of cell energy on maintaining cognitive
performance.TrkB
TFAM
CREB
PGC-1α m
AMPK & SIRT1
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S
Fig. 8. Proposedmechanism bywhich activation of BDNF receptor TrkB using 7,8-dihydroxyﬂav
following traumatic brain injury (TBI). 7,8-DHF is amember of the ﬂavonoid family that crosses
with 7,8-DHF restores the TBI induced disruption of TrkB signaling, which plays a pivotal ac
improves mitochondrial function by activating mitochondrial DNA (mtDNA) transcription, an
mtDNA transcription leads to the synthesis of mitochondrial proteins including cytochrome
(OXPHOS) inmitochondria. ATP and NAD are small molecules involved in all energy transactio
(AMPK) and sirtuin 1 (SIRT1) respectively, which both have the capacity to activate PGC-1α.
mitochondrial energy system, and is important for maintaining cognitive function and synapt
syntaxin-3 and GAP-43. Overall, the diagram illustrates a mechanism by which the interplay be
and injured conditions.4.3. Energy management system, brain plasticity and neuronal signaling
Brain energy metabolism is central to all cellular processes that
maintain neuronal functionality and has the capacity to modulate
synaptic plasticity and behavior [33]. It has been reported that BDNF
stimulates energy metabolism in developing cortical neurons during
energy demand [18] and regulates mitochondrial oxidative efﬁciency
by engaging complex I [19]. ATP and NAD are small molecules involved
in all energy transactions in cells, and can be sensed by regulatory
proteins, such as AMP-activated protein kinase (AMPK, which senses
the AMP/ATP ratio) and sirtuins (which require NAD to deacetylate
protein substrates), which both have the capacity to activate PGC-1α
[34]. PGC-1α is involved in the transcription of genes promoting
mitochondrial biogenesis as well as the mitochondrial anti-oxidant
system to protect neurons against oxidative damage [35,36]. Mitochon-
drial biogenesis constitutes a critical aspect of the AMPK response to
energy deﬁcient states, demonstrated to occur through PGC-1α [16].
SIRT1 deacetylase increases mitochondrial density in neurons by requi-
site activation of the transcriptional activity of PGC-1α [37]. In neurons,
the AMPK–SIRT1–PGC-1α signaling pathway plays a critical role in
energy metabolism by regulating mitochondrial function [16]. Of
these, AMPK is a serine-threonine kinase, which has the ability toGAP-43
tDNA transcription
and replication
OXPHOS and 
mitochondrial
biogenesis
Synaptic plasticity &
cognitive functions
y
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one (7,8-DHF), a small-molecule TrkB agonist, improves brain plasticity andmental health
the blood–brain barrier and activates the TrkB receptor similar to the BDNF. The treatment
tion on mitochondrial biogenesis through metabolic activators such as PGC-1α. PGC-1α
d mitochondrial proliferation through mitochondrial transcription factor A (TFAM). The
c oxidase (COII), which is a key player for ATP production by oxidative phosphorylation
ns in cells, and can be sensed by regulatory proteins, such as AMP-activated protein kinase
The alteration in AMPK–SIRT1–PGC-1α signaling pathway plays a critical role to regulate
ic plasticity via CREB. Regulation of synaptic function by 7,8-DHF can also be mediated by
tween energy management and plasticity regulates neuronal function under homeostatic
871R. Agrawal et al. / Biochimica et Biophysica Acta 1852 (2015) 862–872sense low energy levels and to activate or inhibit molecules to
re-establish the proper energy balance of the cell. According to our
results, TBI reduced the activation of AMPK, an indicator of a distur-
bance in energy homeostasis. In turn, the activation of AMPK with
7,8-DHF advocates that TrkB signaling may activate mechanisms to
conserve ATP levels in the hippocampus. A mechanistic association
between AMPK and SIRT1 seems to exist as NAD, a critical substrate
for SIRT1 function, also activates AMPK in a dose-dependent manner
[38]. The function of SIRT1 has been associated with the control of
cellular homeostasis and energy metabolism [39,40], and our ﬁndings
that TBI reduces SIRT1 levels seem to reﬂect the action of TBI on
energy management. The fact that the treatment with 7,8-DHF normal-
ized SIRT1 levels emphasizes the involvement of TrkB activation in
maintaining energy homeostasis.
SIRT1 (mammalian Sir2 homologue) has been shown to modulate
synaptic plasticity andmemory formation via post-transcriptional regu-
lation of CREB [41]. It has also been reported that AMPK regulates cAMP-
response element binding (CREB) proteins [42], which is a family of
transcription factors, playing a major role in synaptic plasticity and
cognitive functions [28]. TrkB signaling is crucial for the action of CREB
on synaptic plasticity and learning and memory [43]. This implies that
the effects of 7,8-DHF on increasing CREB activation may be signiﬁcant
for modulation of synaptic plasticity. CREB is a potent activator of
PGC-1α [44], which emphasizes the double function of CREB as a
synaptic activator and energy modulator. Furthermore, according to
our results, TBI compromised the molecular systems important for the
maintenance of synaptic plasticity and repair such as GAP-43 and
syntaxin-3. It is reported that synaptic dysfunctions in hippocampal
CA1 such as reduced basal transmission and long-term potentiation
leads to behavioral deﬁcits in mouse model of Alzheimer's disease
[45]. Therefore, the reduced immunoreactivity of syntaxin-3 in den-
drites of CA1 pyramidal cells after FPI might be associated with cogni-
tive dysfunctions. GAP-43 is an intracellular membrane-associated
phosphoprotein, present in growth cones and pre-synaptic terminals
important for formation of neuronal connections, and synaptic remod-
eling following traumatic insult [29]. In addition, GAP-43 has also
been suggested as an important mediator for the neurotrophic effects
of BDNF on neuronal survival and plasticity [46]. The treatment with
7,8-DHF counteracted the TBI induced reductions in GAP-43 and
syntaxin-3 at protein and phenotypic expression levels, suggesting an
action of TrkB activation on synaptic plasticity and growth. Based on
these results, it appears that TrkB signaling is pivotal for engaging
signals related to synaptic plasticity and energy management.
In summary, our results show that TBI disturbs pathways associated
with energy homeostasis and synaptic plasticity, and that 7,8-DHF
counteracted these disturbances. The action of 7,8-DHF is associated
with key molecular events of mitochondrial biogenesis and synaptic
plasticity with important implications for cognitive function (Fig. 8).
The overall results provide insight to understand how metabolic and
plasticity signals interact with each other to inﬂuence long-term
neuronal resilience against neurological and psychiatric disorders.
The results also portray 7,8-DHF as an effective therapeutic agent to
counteract crucial aspects of the broad TBI pathology.Transparency Document
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